Blood transfusions for anaemia in patients with advanced cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2012, Pages

  Preston, Nancy J ^a   Hurlow, Adam ^b   Brine, Jennifer ^c   Bennett, Michael I ^d  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; BLOOD TRANSFUSION; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; HUMAN; MORTALITY; NEOPLASM; RECURRENT DISEASE; REVIEW; TIME;

ANEMIA; BLOOD TRANSFUSION; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; HUMANS; NEOPLASMS; RECURRENCE; TIME FACTORS;

EID: 84861321751     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009007.pub2     Document Type: Review

References (60)

1. Brown E, Bennett M. Survey of blood transfusion practice for palliative care patients in Yorkshire: implications for clinical care. Journal of Palliative Medicine 2007;10:919-22.
2. Brown E, Hurlow A, Rahman A, Closs SJ, Bennett MI. Assessment of fatigue after blood transfusion in palliative care patients: a feasibility study. Journal of Palliative Medicine 2010;13:1327-30.
3. Gleeson C, Spencer D. Blood-transfusion and its benefits in palliative care. Palliative Medicine 1995;9:307-13.
4. Laird BJA, Whyte G, Laird JH, Soutar RL, Welsh J, Fallon MT. An observational study of red cell transfusion in specialist palliative care. Palliative Medicine 2008;22:874-5.
5. Lau SC, Tsai WYCCH. Comparison of outcomes of blood transfusion in non-hospice and hospice terminal cancer patients in a district hospital. Fu-Jen Journal of Medicine 2006;4:83-9.
6. Mercadante S, Ferrara P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. Journal of Palliative Medicine 2009;12:60-3.
7. Monti M, Castellani L, Berlusconi A, Cunietti E. Use of blood transfusions in terminally ill cancer patients admitted to a palliative care unit. Journal of Pain and Symptom Management 1996;12:18-22.
8. Morey PJ. Blood transfusion in palliative care - who benefits?. European Association for Palliative Care 8th Congress, The Hague. 2003.
9. Tanneberger S, Melilli G, Strocchi E, Frenquelli C, Pannuti QF. Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents?. Annals of Oncology 2004;15:839-44.
10. Vassallo E, Piccione T, Pirajno G, Palazzolo B, Trizzino G. Miglioramento della qualità di vita in pazienti terminali con anemia severa sottoposti a trasfusione domiciliare. Rivista Italiana di Cure Palliative 2006;4:30-6.
11. Wachtel T, Mor V. The use of transfusion in terminal cancer patients. Hospice versus conventional care setting. Transfusion 1985;25:278-9.
12. Yang GM, Light D, Bengston KA. Indications and benefits of blood transfusions in a hospice setting. European Journal of Palliative Care. 2011; Vol. 18:256-7.
13. Martinsson U, Lundström S. The use of blood transfusions and erythropoietin-stimulating agents in Swedish palliative care. Supportive Care in Cancer 2009;17:199-203.
14. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327(7414):523.
15. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Journal of Respiratory Critical Care Medicine 1999;159:321-40.
16. Anon. NHS blood and transplant saving lives together. Annual Review 2008/2009 2009:13-4.
17. Basha J, Dewitt RC, Cable D, Jones GP. Transfusions and their costs: managing patients needs and hospitals economics. The Internet Journal of Emergency and Intensive Care Medicine 2006;9(2):www.ispub.com/ostia/index.php?xmlPrinter=true&xmlFilePath=journals/ijeicm/vol9n2/cost.xml.
18. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2]
19. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. Journal of Pain and Symptom Management 2000;19(5):357-62.
20. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology 2001;19(14):3385.
21. Chan KS, Sham MMK, Tse DMW, Thorsen AB. Palliative medicine in malignant respiratory diseases. In: Doyle D, Hanks G, Cherny N, Calman K editor(s). Oxford Textbook of Palliative Medicine. 3rd Edition. Vol. 3, Oxford University Press, 2005:587-618.
22. Conill C, Verger E, Henríquez I, Saiz N, Espier M, Lugo F, et al. Symptom prevalence in the last week of life. Journal of Pain and Symptom Management 1997;14(6):328-31.
23. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006145.pub2]
24. Cremieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology 2000;18(14):2755.
25. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Journal of Clinical Oncology 1998;16(10):3412.
26. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliative Medicine 2007;21(3):177.
27. Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. Journal of Pain and Symptom Management 1998;16(4):212-9.
28. Dunn A, Carter J, Carter H. Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. Journal of Pain and Symptom Management 2003;26(6):1132-9.
29. EPOC methods paper including interrupted time series (ITS) designs in a EPOC review. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/inttime.pdf 1998.
30. Falk K, Swedberg K, Gaston-Johansson F, Ekman I. Fatigue and anaemia in patients with chronic heart failure. European Journal of Heart Failure 2006;8(7):744.
31. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology 2001;19(11):2875.
32. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology 1997;15(3):1218.
33. Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer-related fatigue. Journal of Pain and Symptom Management 2003;26(1):604-14.
34. Indelicato RA. The advanced practice nurse's role in palliative care and the management of dyspnea. Topics in Advanced Practice Nursing eJournal 2006;6(4):Accessed on 12 January 2011 from: http://search.medscape.com/medscape-search?queryText=indelicato.
35. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999;281(18):1714-7.
36. Jennings AL, Davies AN, Higgins JPT, Anzures-Cabrera J, Broadley KE. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002066]
37. Ledingham IM. Factors influencing oxygen availability. Journal of Clinical Pathology 1977;3(1):1.
38. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2001;19(11):2865.
39. McClelland DBL. Handbook of Transfusion Medicine. Vol. 12, Crown, 2007:390.
40. Meek PM, Lareau SC. Critical outcomes in pulmonary rehabilitation: assessment and evaluation of dyspnea and fatigue. Journal of Rehabilitation Research and Development 2003;40(5 (Suppl 2)):13-24.
41. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients. Cancer 1999;85(5):1186-96.
42. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3]
43. Mock V, Abernathy AP, Atkinson A, Barsevick AM, Berger AM, Cella D. NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue. Journal of the National Comprehensive Cancer Network 2007;5:1054-78.
44. Morgan K. Fatigue and lethargy in palliative care. InnovAit 2010;3(4):225.
45. Nekolaichuk C, Watanabe S, Beaumont C. The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991-2006). Palliative Medicine 2008;22(2):111-22.
46. Noergaard Munch T, Zhang Z, Willey J, Lynn Palmer J, Bruera E. The association between anaemia and fatigue in patients with advanced cancer receiving palliative care. Journal of Palliative Medicine 2005;8:1144-9.
47. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Pharmacotherapy 1986;89(2):234.
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
49. Schwartz AH. Validity of cancer-related fatigue instruments. Pharmacotherapy 2002;22(11):1433-41.
50. Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, et al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Annals of Oncology 2005;16(9):1545.
51. Sood A, Moynihan TJ. Cancer-related fatigue: an update. Current Oncology Reports 2005;7(4):277-82.
52. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliative Medicine 2009;23(4):325.
53. Stone P, Hardy J, Broadley K, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. British Journal of Cancer 1999;79(9/10):1479.
54. Stone P, Richards M, A'hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of Oncology 2000;11(5):561.
55. Sweeney C, Neuenschwnader H, Bruera E. Fatigue and asthenia. Oxford Textbook of Palliative Medicine. 3rd Edition. Oxford University Press, 2005:560-6.
56. Turner A. Clinical management of anemia, cytopenias and thrombosis in palliative medicine. Oxford Textbook of Palliative Medicine. 3rd Edition. Oxford University Press, 2005:568-72.
57. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfusion Medicine 2003;13(4):205-18.
58. Wells AW, Mounter PJ, Chapman CE, Stainsby D, Wallis JP. Where does blood go? Prospective observational study of red cell transfusion in north England. BMJ 2002;325(7368):803.
59. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management 1997;13(2):63-74.
60. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "It feels like my body is just worn out". JAMA 2007;297(3):295.